INTRODUCTION
Chronic myeloid leukemia (CML) is a haematopoietic neoplasm characterized by cytokine-independent myeloproliferation, multi-step evolution with clinically distinct phases of the disease and the BCR⁄ABL1 oncogene.
1 Almost 95% of patients with chronic myeloid leukemia (CML) show positive Philadelphia chromosome 22q, which results from a fusion reciprocal translocation among chromosomes 9 and 22.
2 The production of fusion protein, BCR-ABL through the activation of downstream signaling pathways causes constitutively cell transformation. BCR-ABL1, 210 kDa sized cytoplasmic fusion gene oncoprotein contribute critically to the manifestation and progression of CML.
3,4 BCR-ABL is clinically classified into chronic phase, accelerated phase and aggressive leukemic phase called blast phase. [5] [6] [7] Before the Imatinib approval by US FDA in 2001 there was no specific targeted drug therapy to change the natural progression to CML, Although cytotoxic drugs such as Busulfan, Hydroxy Urea and Interferon (Inf)-alpha were used. 8 However there was no long lasting response for the patients on such cytotoxic chemo therapy and relapse was observed in most patients.
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EVOLUTION OF IMATINIB
Imatinib mesylate, a potent inhibitor of BCR-ABL was the first major breakthrough in target cell therapy and has shown highly effective cytogenetic response in clinical trials. 11, 12 In a phase II clinical trial the patients in chronic who were not responding to interferon-alpha 95% of the patients achieved complete haematological response and 60% achieved cytogenetic response. 13 Another phase III trial in newly diagnose diseases a superior haematological response and cytogenetic response was observed with Imatinib compare to Interferon (Figure 1 ).
Strategic therapeutic approaches to overcome emerging dual SRC/ABL kinase inhibitors resistances in chronic phase Ph positive chronic myeloid leukemia EMERGENCE OF IMATINIB RESISTANCE
Soon after the introduction of Imatinib investigators began to describe in-vitro derived cell line with resistance to the drug. The therapeutic response assessed with Imatinib is based upon meeting hematologic, cytogenetic, molecular mile stones established by National Comprehensive Cancer Network (NCCN). 14, 15 Patients that fail to achieve defined responses at predefined chronological time points are described as primarily resistant to therapy and those loosing previously obtained mile stones in diseases are termed secondarily resistant. 16 The patients with suspected treatment failure and thus suspected resistance, all diagnostic test including a complete re staging and re-biopsy of Bone Marrow (histology, morphology, chromosome analysis, FISH), BCR-ABL1 mRNA level and screening for BCR-ABL mutation should be performed and karyogram should be reported on the percentage of Ph+ cell and for additional chromosome abnormalities. [17] [18] [19] Predominantly Imatinib resistance was clinically classified as BCR-ABL dependent and independent mechanism. The dependent mechanism is further categorized as BCR-ABL duplication leading to higher expression of pathogen, BCR-ABL mutation manifesting as point mutation, P loop mutation, T315I mutation, C helix, SH2 domain, subtract binding site, activation loop, C terminal lobe by amplification or overexpression of independent pathways eg. SRC family kinase activation. Alternative mechanisms include over expression of P-glycoprotein efflux pump deregulation of SRC family of tyrosine kinases (SFK) activity and activation of other pathways. Further low expression, activity or polymorphism of organic cation transporter1 significantly produces intra cellular level of Imatinib due to restricted drug import.
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ADVENT OF 2
ND
GENERATION TYROSINE KINASE INHIBITOR: NILOTINIB
Although escalation of Imatinib does shown to overcome primary resistance but the short acting response, resistance and intolerance led to choice of alternative drug with improve potency and ability to prevent the emergence of drug resistance clones acting in different pathway improving response rate and potential increase in survival. Nilotinib, a second generation phenyl amino pyrimidine derivative structurally similar to Imatinib was found 10 to30 folds more potent than Imatinib in inhibiting activity of BCR-ABL kinase in proliferation of Ph expressing cells.
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It effectively inhibit the auto phosphorylation of BCR-ABL tyrosine 177 involved in CML pathogenesis. It binds to the inactive conformational of the ABL kinase domain mostly through the lipoprotein interaction by making 4 hydrogen bonds involving the Pyridyl-N and the back bone NH of Met-318, the Anilino-NH and the side chain OH of Thr-315, the Amido-NH and side chain carboxylate of Glu-286 and the Amido carboxyl with back bone NH of the ASP 381. 24, 25 Nilotinib is effective against most mutation associated with Imatinib but remains resistant to T315I mutant as a consequence of loss of a H bond interaction between threonine-O and aniline-NH on Nilotinib and a steric clash between the Isoleucine-methyl group and 2-methyl phenyl group of nilotinib 23 ( Figure 1 ).
Nilotinib appears to target the inactive ABL domain yet it has demonstrated activity against multiple Imatinib resistance mutations. Organic Cation transporter (OCT1) has no role in cellular import of Nilotinib although it does appear to be a substrate for Pgp. 26 Nilotinib has potential drug targets as BCR-ABL kinase, KIT, PDGFR 
DEVELOPMENT OF DUAL SRC FAMILY KINASE/ ABL INHIBITOR: DASATINIB
The extensive understanding of mechanism of Imatinib resistance has prompted the search for alternate BCR inhibitors which can act as dual Src family kinase and ABL inhibitor ( Figure 1 ). Strategic rational drug design led to Dasatinib, a novel orally available small molecule multi targeted kinase inhibitor that potentially inhibits BCR-ABL and Src family and is 325 fold more potent than Imatinib against cell expressing wild type BCR-ABL. 27 This multi kinase inhibitor active against ABL mutation and many other tyrosine kinase family which are Imatinib resistant, such as platelet derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), KIT and Src family kinase. 28 Dasatinib binds to Abl with less stringent conformational requirements than Imatinib and there by an increased potency is exhibits but reduces selectivity compare to Imatinib. 29 An x-ray crystal structure of human ABL kinase domain (residues 225 to 512) complex with Dasatinib at 2.4 Ǻ resolution encompasses the cardinal structural features of an activated protein kinase separated in two lobes ( Figure 2 ). The smaller NH2 terminal lobe is composed of I prominent helix α-c and five stranded β sheet. A single poly peptide strand acting as a hinged connects the two lobes which can rotate with respect to one another on ATP binding. The highly flexible P-loop connecting β1 and β2 strands, contains a glycine rich sequence motif (GXGXφG) where φ is tyrosine and phenyl alanine caps the site of phosphate transfer under . These residues in ABL-Dasatinib structure super imposed well with activated LCK structure. A conserved Lys271-Glu286 salt bridge orients glycine side chain for interacting ATP phosphatase and maintains an active kinase conformation. There by affirming binding of Dasatinib to activated ABL kinase 30 ( Figure 2 ).
Side chain of Q252 contribute to the distorted P loop conformation by packing up against Y253 which leads to Imatinib interaction and hydrogen bonds with N322, Y253 does not interact with Dasatinib but the hydroxyl of Y253 hydrogen bonds with back bone of R367, an interaction that must not be critical due to Dasatinib against Y253f mutant E255 hydrogen bonds to its own back bone in Dasatinib bound form whereas in Imatinib bound form, it hydrogen bonds with the hydroxyl of Y257, stabilizing Imatinib bound conformation of the p loop. 
COMPARISON OF DASATINIB COMPLEX WITH IMATINIB COMPLEX
Dasatinib has grater potency against BCR-ABL a striking structural difference exist between Abl-Dasatinib complex and ABL-Imatinib complex. (Figure 3 Figure 2 ).
Dasatinib is the first dual BCR-ABL kinase inhibitor and
Src family kinase inhibitor which efficiently overcome Imatinib resistant Abl mutations. Dasatinib was found to be active against 15 clinically significant Imatinib resistant BCR-ABL mutation comprising 12 altered amino acid locations (T315I, Y253F/H, M244V, H396R, G250E, Q252H/R, E255K/V, F486S, M351T, F359V, E355G and F317L) (Figure 3 ).
Early recognition of mutant clones offers clinical benefits.
Nine mutations associated with the substitution of 6 amino acid residues F317L (TTC3TTG, TTC3TTA, TTC3CTC), V299L (GTG3CTG, GTG3TTG), M244V (ATG3GTG), E355G (ATG3GTG), F311I (TTC3ATC) and F359V (TTC3GTC) are vastly pertinent with respect to resistance to second generation TKIs.
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RATIONAL DRUG DESIGNING: TARGETED THERAPEUTIC APPROACHES IN OVERCOMING T315I
The frequency of T315I mutation in BCR ABL1 mutated Chronic Myeloid Leukemia is 20.2%.There only two mutation which were clearly resistant to Dasatinib and retained kinase activity on presence of micromolar concentration of Dasatinib. An approach translating amino acids location in mutant in crystal structure of ABL kinase in Dasatinib reveals remarkably significant insights regarding the mutations. A Van der wall contact between 2 chloro 6 methyl phenyl group of Dasatinib and side chain methyl group of amino acid location in Abl kinase crystal structure.
It is postulated that T315I mutation is most probably due to loss of a hydrogen bond that involves Dasatinib with the side chain of T315 which is critical contact point for Dasatinib. Another reason for T315 resistance can be due to the increase steric bulk in this pocket. There by it is suggested that the apparent ability of Dasatinib to acknowledge multiple states of the enzyme lead to a greater Abl binding affinity of Dasatinib over Imatinib. Hence a critical interaction between Dasatinib and Thr315 of the hinged region of the fusion complex causes loss of activity against T315I mutation. The higher rate of genomic instability may foster the development overtime of multiple mutation within the same or indifferent BCR-ABL positive sub clones, which are selected or deselected in accordance to the resistance to the inhibitor employed and the spectrum of sensitivity. 34 The T315 is observed in 15% of Ph + leukemic patients who are Imatinib positive.
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To create a specific panel of assays to monitor Nilotinib and Dasatinib resistance the genotyping efforts should be restricted to a small number of limited candidate mutation that confer resistance to a particular drug. Nicolini reported a decrease progression free survival and overall survival for the patients harboring T315I alteration and P loop mutations like G250E, Y253F-H and E255/V (Figure 4 ).
All though this resistance seems to be troublesome but it can be considered as a downfall of targeted therapy in cml. In the three major retrospective studies exploring the incidence of Abl Kd mutation in Imatinib patients conducted to compare the frequency of T315I mutations and P loop mutation reported that incidence of T315i was 4%, 11% and 19% respectively whereas incidence of P loop mutation was much higher being 28%, 46% and 39% respectively. 35 The T315I mutation as is evidently more prevalent in chronic phase CML.Nevertheless now a day's vast majority of the patients are early chronic phase cml who receive Imatinib at first line therapy.
DISCUSSION
A strategic therapeutic approach is to design the targeted agents which can act with a different mode of action for example the drugs that target the BCR-ABL or BCR-ABL downstream signal transducer alone or in combination with another BCR-ABL kinase inhibitor (Table 1) .
Recently histone-deacetylase inhibitor Panobinostat (LBH589) which depletes BCR-ABL and induce growth arrest and causes death of cells expressing t315i BCR-ABL, when administered alone and highly effective when administered with Nilotinib. 26 Another histone-deacetylase inhibitor Vorinostat also called as Suberoylanilide Hydroxamic acid (SAHA) when given alone or in combination with Dasatinib has shown promising results in several malignant conditions.
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Many trials are assessing combination of Vorinostat with conventional agents to overcome various resistances in CML patients. Panobinostat (LBH589) F317L is another significant mutation that turns out to be a problematic mutant in Dasatinib resistance. F317 was observed to make off-center aromatic π stacking with pyrimidine and thiazo ring of Dasatinib which explains slight loss in activity of Dasatinib against F317L mutation.
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G250E mutation reduces the flexibility of P loop and inhibit P loop to adopt Imatinib induce conformation whereas Dasatinib exhibits an improve activity against G250 mutation which arises due to low priority of P loop interaction of Dasatinib.
Ponatinib is a multi targeted tyrosine kinase inhibitor targets Abl, fibro blast growth factor receptor 1 (FGFR1), fmslike tyrosine kinase receptor-3(FLT3), vascular endothelial growth factor receptor, KIT and potent inhibitor of T315I mutation and indicated in Ph + CML, acute lymphoblastic leukemia and other advanced haematological malignances. X-ray crystallographic analysis of Ponatinib in T315I BCR-ABL mutated kinase demonstrates that imidazole pyridazine core rest in adenine pocket of enzyme (Figure 1) . The methyl phenyl group occupies a hydrophobic group behind t315, the ethylene linkage forms a favorable Vander wall interaction with amino acids and the trifloro methyl group binds to pocket induced by the active conformation kinase, in the hinged region 5 hydrogen bonds are generated with the back bone of Met318 along with the side chain Glu286 and protonated methyl piprazine with the back bone carbonyl atoms of Ile360 and His361.
CONCLUSION
With many novel drug molecule availability of second and third generation tyrosine kinase inhibitors and stem cell targeting drugs promise a brighter outlook of success in CML patients. The propensity of Ph + CML to develop novel mechanism of resistance offers a formidable challenge and has stimulated the research in numerous dynamic arenas like designing rational therapeutic approaches to eradicate the minutest residual diseases so 
